Table 6

Quality of Life (EQ-5D-3L) by time since last checkpoint inhibitor dose*

% Reporting symptoms†
Overall (n=90)<24 months (n=37)24 to <36 months (n=27)36+months
(n=26)
Some/ moderateYesSome/moderateYesSome/moderateYesSome/moderateYes
Mobility190140190270
Self-care40500080
Activity230240220230
Pain301223330390
Anxiety391380374420
  • *There were no statistically significant differences based on sex or time since treatment in the reporting of no symptoms versus any symptoms (some/moderate/yes combined).

  • †Remaining participants responded ’No’.